563 related articles for article (PubMed ID: 35608633)
21. Distribution of Antimicrobial Resistance and Virulence Genes within the Prophage-Associated Regions in Nosocomial Pathogens.
Kondo K; Kawano M; Sugai M
mSphere; 2021 Aug; 6(4):e0045221. PubMed ID: 34232073
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of distribution and drug resistance of pathogens from the wounds of 1 310 thermal burn patients].
Zhang C; Gong YL; Luo XQ; Liu MX; Peng YZ
Zhonghua Shao Shang Za Zhi; 2018 Nov; 34(11):802-808. PubMed ID: 30481922
[No Abstract] [Full Text] [Related]
23. Surveillance and comparison of antimicrobial susceptibility patterns of ESKAPE organisms isolated from patients with bacteraemia in South Africa, 2016 - 2017.
Ismail H; Lowman W; Govind CN; Swe Swe-Han K; Maloba MRB; Bamford C; Perovic O
S Afr Med J; 2019 Nov; 109(12):934-940. PubMed ID: 31865955
[TBL] [Abstract][Full Text] [Related]
24. Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines.
Berti F; De Ricco R; Rappuoli R
Molecules; 2018 Jun; 23(6):. PubMed ID: 29865239
[TBL] [Abstract][Full Text] [Related]
25. Emerging Antimicrobial Resistance.
Flynn CE; Guarner J
Mod Pathol; 2023 Sep; 36(9):100249. PubMed ID: 37353202
[TBL] [Abstract][Full Text] [Related]
26. Glycoconjugate vaccines: an update.
Vella M; Pace D
Expert Opin Biol Ther; 2015 Apr; 15(4):529-46. PubMed ID: 25496172
[TBL] [Abstract][Full Text] [Related]
27. The role of vaccines in combating antimicrobial resistance (AMR) bacteria.
Alghamdi S
Saudi J Biol Sci; 2021 Dec; 28(12):7505-7510. PubMed ID: 34867055
[TBL] [Abstract][Full Text] [Related]
28. Glycoconjugate vaccines: current approaches towards faster vaccine design.
Micoli F; Del Bino L; Alfini R; Carboni F; Romano MR; Adamo R
Expert Rev Vaccines; 2019 Sep; 18(9):881-895. PubMed ID: 31475596
[No Abstract] [Full Text] [Related]
29. [In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010].
Yamaguchi K; Ohno A; Ishii Y; Tateda K; Iwata M;
Jpn J Antibiot; 2012 Jun; 65(3):181-206. PubMed ID: 23173294
[TBL] [Abstract][Full Text] [Related]
30. Improving protein glycan coupling technology (PGCT) for glycoconjugate vaccine production.
Dow JM; Mauri M; Scott TA; Wren BW
Expert Rev Vaccines; 2020 Jun; 19(6):507-527. PubMed ID: 32627609
[TBL] [Abstract][Full Text] [Related]
31. [Microbiological characteristics of patients with severe burns caused by blast and application of meta- genomics next-generation sequencing in the detection of pathogenic microorganisms].
Luo RB; Huang M; Hu H; Zhang R; Han CM
Zhonghua Shao Shang Za Zhi; 2021 Oct; 37(10):946-952. PubMed ID: 34689464
[No Abstract] [Full Text] [Related]
32. Impact and Control of Sugar Size in Glycoconjugate Vaccines.
Stefanetti G; MacLennan CA; Micoli F
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234967
[TBL] [Abstract][Full Text] [Related]
33. Partnering on vaccines to counter multi-drug resistant threats: Workshop proceedings, Biomedical Advanced Research and Development Authority.
Bergmann JN; Killen-Cade RR; Parish LA; Albrecht MT; Wolfe DN
Hum Vaccin Immunother; 2022 Nov; 18(5):2058840. PubMed ID: 35417305
[TBL] [Abstract][Full Text] [Related]
34. Immunization as a tool to combat antimicrobial resistance.
Spika J; Rud EW
Can Commun Dis Rep; 2015 Nov; 41(Suppl 5):7-10. PubMed ID: 29769969
[TBL] [Abstract][Full Text] [Related]
35. Trends in antimicrobial resistance of bacterial pathogens in Harare, Zimbabwe, 2012-2017: a secondary dataset analysis.
Mhondoro M; Ndlovu N; Bangure D; Juru T; Gombe NT; Shambira G; Nsubuga P; Tshimanga M
BMC Infect Dis; 2019 Aug; 19(1):746. PubMed ID: 31455256
[TBL] [Abstract][Full Text] [Related]
36. Acquired Genetic Elements that Contribute to Antimicrobial Resistance in Frequent Gram-Negative Causative Agents of Healthcare-Associated Infections.
Cruz-López F; Villarreal-Treviño L; Camacho-Ortiz A; Morfín-Otero R; Flores-Treviño S; Garza-González E
Am J Med Sci; 2020 Dec; 360(6):631-640. PubMed ID: 32747008
[TBL] [Abstract][Full Text] [Related]
37. The role of vaccines in fighting antimicrobial resistance (AMR).
Jansen KU; Anderson AS
Hum Vaccin Immunother; 2018; 14(9):2142-2149. PubMed ID: 29787323
[TBL] [Abstract][Full Text] [Related]
38. Recent mechanistic insights on glycoconjugate vaccines and future perspectives.
Berti F; Adamo R
ACS Chem Biol; 2013 Aug; 8(8):1653-63. PubMed ID: 23841819
[TBL] [Abstract][Full Text] [Related]
39. Glycoengineered Outer Membrane Vesicles as a Platform for Vaccine Development.
Valguarnera E; Feldman MF
Methods Enzymol; 2017; 597():285-310. PubMed ID: 28935107
[TBL] [Abstract][Full Text] [Related]
40. Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs.
Berti F; Micoli F
Curr Opin Immunol; 2020 Aug; 65():42-49. PubMed ID: 32361591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
